TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: patient's satisfaction (SAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity of vaccine, as assessed by neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of vaccine, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of vaccinees infected with this dengue virus subtype 2 (DEN2) candidate vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive performance as measured by the MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Toxicity of gemcitabine monochemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Activity of gemcitabine monochemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of cisplatin-based polychemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Activity of cisplatin-based polychemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent neointimal hyperplasia volume obstruction (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Volume of postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Unit of blood transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Objective response rate (partial or complete response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Video analysis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Gamma Glutamyl Transferase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dietary quality and intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in physical activity and sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sensitivity and specificity of urinary dipstick for proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on patient treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squamo-columnar junction vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptoms Measured by Young Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between novel biomarkers and primary rheumatology diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety symptoms over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance of disease-free state
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of death at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in motor development and motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in [11C]-(+)-PHNO binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ultrasound visibility of anatomical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean abdominal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum abdominal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of portable monitoring device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine response of circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bleb vascularity grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Pain on Activities and Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants with complete renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local orbital control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite perinatal morbidity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Equivalent safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Patients wish for place of death and place of terminal care fulfilled
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Relative amount of time spent in hospital in the terminal phase
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: A subjective measure of the patients symptoms and quality of life (EORTC-QLQ-15-PAL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in Headache Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of EMT Strategies Used by Parents
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of multiple myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in gingival bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endometrial tissue and peripheral blood mononuclear cells receptivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: biochemical data - albumin and hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of MSM tested for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants obtaining CD4 results and ART eligibility assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct rate of identifying consumers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Birch-SPIRE administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Frailty development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of complete spontaneous bowel movements (CSBMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of pepsin in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of snoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Z-208
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brief Pain Inventory (BPI) short form
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Delay in autonomic nervous system activity to brain death confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in lipid pool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Lower Eyelid Bags
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medications used prior to admission associated with worse infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Modus RELF-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction rate of serum VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy in AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Absence of reflux in the treated SSV segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Subcutaneous Fat Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With a Histologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Regression of lesions (reduction of fibrofolliculoma size and count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients With Complete Response During Chemotherapy Course 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD Checklist scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Handwashing adherence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: variation of HDRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volumetric response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: age at conization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pharmacokinetic half life of NAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic half life of calcitriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glutathione concentration in Basal ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bowel Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bladder Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sexual Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area Under the Curve for efavirenz (AUC0-192)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration for efavirenz (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to infinity for efavirenz (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dislocation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Past 30 day drug use abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Recruitment Process
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance of Treatment Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of Follow-up Assessment at Three Months After the End of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of sero-epidemiological programme
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of correct classifications for FNA biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC and Cmax of CMX001 and cidofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotic listening performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Speech discrimination in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Temporal processing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Gastric antral area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety Event Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Failure Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar puncture success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of ICU delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Median HIT-6 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improve in NDI by ≥ 15 points at 24 months compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: No device failures requiring revision, re-op or removal
Endpoint domain: Adverse events/effects
Primary endpoint: No major complications, i.e., vascular or neurological injury
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance or improvement of neurologic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline ASIA Rating Scale at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline ASIA Rating Scale at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline EMG at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline EMG at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation between urinary biomarkers and NL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with reduction in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Non progression rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in expression of intestinal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor growth control rate (CR, PR, SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of Left Ventricular Filling Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of systolic blood pressure and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GSH levels in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of SR and AC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Newborn mortality
Endpoint domain: Mortality/survival
Primary endpoint: Maternal hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Newborn hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: MRI sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous complete remission rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPS stimulated TNF-α production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Noninvasive ventilation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peri-implant mucosa margin position change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC A1 pain when walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinonasal gas exchange rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach 50% of Maximum Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Reach 50% of Maximum Glucagon Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Satisfaction survey improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of otitis media care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Amount of time spent by nurses on patient urinary care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ultrasound pulmonary variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Report of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efavirenz AUC0-inf and AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Oswestry Low Back Pain Disability Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, relatedness, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participant with device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total breast volume resected during breast conserving surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with positive surgical margins as assessed by pathological examination of the specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in inhibition of platelet aggregation in platelet rich plasma (PRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in thromboxane receptor occupancy (TRO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in thromboxan synthesis inhibition (TSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of bone repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concentration of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hyperglycemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Western Ontario Shoulder Instability score (WOSI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Viable pregnancy rate one month after embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of syndecan-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of early postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Chemoreflex gain on exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any AIDS-defining Condition
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PTS Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of Screening Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of JHS in functional dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Indicated Non-progressive Disease (Investigator Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Indicated Non-progressive Disease (Independent Radiologist Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes